Upregulation of CD46 and CD55 protects cancer cells from complement-dependent cytotoxicity, and the inhibition of these targets may be used as a strategy to enhance the effect of anticancer antibodies, like trastuzumab in HER2+ BC [48]. Here, CD46 is linked to breast cancer.